A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Study summary

This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedAB308 and Zimberelimab

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 28, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?22 U.S. locations

Locations may change over time.

Who runs it?Arcus Biosciences, Inc.

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1
Sponsor: Arcus Biosciences, Inc.
Interventions being studied: Drug: AB308; Drug: Zimberelimab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent.
Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Adequate organ and marrow function

Reasons someone may not be able to joinExclusion criteria

History of trauma or major surgery within 28 days prior to the first dose of study treatment.
Prior treatment with an anti-TIGIT antibody.
Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.
Discontinued prior immunotherapy for immune related adverse events with a high severity. NOTE: Other protocol defined Inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

UCLA Department of Medicine - Hematology/OncologyLos Angeles, California
Mayo Clinic Jacksonville - PPDSJacksonville, Florida
Goshen Health SystemGoshen, Indiana
Holden Comprehensive Cancer CenterIowa City, Iowa
Norton Cancer Insititute-DowntownLouisville, Kentucky
Mayo Clinic RochesterRochester, Minnesota
Columbia University Medical CenterNew York, New York
Ohio State University Comprehensive Cancer CenterColumbus, Ohio
University of Oklahoma Peggy and Charles Stephenson Cancer CenterOklahoma City, Oklahoma
University of Pittsburgh Medical CenterPittsburgh, Pennsylvania
Tennessee Onocology - NashvilleNashville, Tennessee
START South Texas Accelerated Research TherapeuticsSan Antonio, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 28, 2025. Always confirm current availability with the study team.

View original record ↗